Purpose Previous studies have examined the association between ABO blood group and ovarian cancer risk, with inconclusive results. Methods In eight studies participating in the Ovarian Cancer Association Consortium, we determined ABO blood groups and diplotypes by genotyping 3 SNPs in the ABO locus. Odds ratios and 95 % confidence intervals were calculated in each study using logistic regression; individual study results were combined using random effects meta-analysis. Results Compared to blood group O, the A blood group was associated with a modestly increased ovarian cancer risk: (OR: 1.09; 95 % CI: 1.01-1.18; p = 0.03). In diplotype analysis, the AO, but not the AA diplotype, was associated with increased risk (AO: OR: 1.11; 95 % CI: 1.01-1.22; p = 0.03; AA: OR: 1.03; 95 % CI: 
Introduction
Ovarian cancer is the fifth leading cause of cancer death for women in the US and the seventh most fatal worldwide [1, 2] . There are few confirmed risk factors for ovarian cancer and no current strategies for early detection and screening. Thus, the identification of new risk factors for ovarian cancer is critical for developing early detection and screening methods. Several studies of ABO blood group (derived from serologic testing) and ovarian cancer risk, comparing cases to either hospitalbased or blood donor controls, suggest increased risk of ovarian cancer with the A blood group compared to the O blood group [3] [4] [5] [6] . However, a recent analysis using self-reported blood type from the Nurses' Health Study (NHS) reported increased ovarian cancer risk associated with the B allele (i.e., blood types AB or B) [7] . To address these inconsistent findings, we imputed ABO blood group using 3 SNPs from the ABO locus in eight studies participating in the Ovarian Cancer Association Consortium (OCAC) and evaluated the associations of ABO blood group (A, AB, B, or O) as well as diplotype (AA, AO, AB, BB, BO, or OO) with risk of ovarian cancer. Further, the A blood group can be divided into two main subtypes: A1 and A2. These subtypes are very similar, except that the A2 allele has a deletion of a single nucleotide, resulting in a frameshift that adds 21 amino acids to the protein product, resulting in diminished enzyme activity [8] . Thus, we used information from one of the SNPs to separate the A1 and A2 alleles and test whether associations differed between the two alleles. We further investigated whether the associations differ by histologic subtype or between normal weight and overweight women, as previously reported in the NHS [7] .
Materials and methods

Study populations and genotyping
Details of the eight studies that participated in this analysis have been published previously [9] [10] [11] These UK sources will be collectively referred to as UKG.
ABO blood groups were inferred by estimating haplotypes of 2 SNPs in the ABO locus. In 60 HapMap phase 2 Caucasians, haplotypes estimated from rs687289 and rs8176746 were perfectly correlated (r 2 = 1) with the O and B blood types, respectively [12] ; however, rs687289 was not included in the genome-wide association study (GWAS) platforms utilized by studies included in this analysis. Therefore, we genotyped rs505922, which is in perfect LD with rs687289 in HapMap2 samples. Additionally, we genotyped rs8176704, which distinguishes the A1 from the A2 allele [13] . In all studies except NEC and NHS, the ABO SNPs were genotyped as part of an ovarian cancer GWAS [14] (Supplemental Table 1 ). For POL, genotyping was conducted using the Illumina 660 W-Quad chip. For TOR, NCO, MAY, TBO, and UKG cases, the Illumina 610 K chip was used; for UKG controls, the Illumina 550 K chip was used; and for NEC and NHS, genotypes were determined using Taqman. For the highthroughput genotyping, the following quality control criteria were met for all three SNPs: (1) no deviation from Hardy-Weinberg equilibrium (p [ 10 -4 ) and (2) not monomorphic and (3) call rate [95 %. Duplicate concordance was [99.99 % for both platforms [14] . For the Taqman genotyping, 10 % of the samples were run in duplicate. Duplicate concordance was 100 % and all 3 SNPs were in Hardy-Weinberg equilibrium.
Statistical methods
All analyses were restricted to subjects of European background. Blood groups were determined by estimating haplotypes of the three genotyped SNPs. Main analyses were conducted for both blood group (A, AB, B vs. O) and for diplotypes (AA, AO, AB, BB, BO vs. OO). Odds ratios (ORs) and 95 % confidence intervals (CIs) were determined using unconditional logistic regression for each study population. Study-specific estimates were combined using random effects meta-analysis. The Q statistic was used to test for heterogeneity between studies. Analyses in each study were adjusted for age, except UKG, which was unadjusted. NEC was additionally adjusted for enrollment phase (1992-1997 or 1998-2002) ; NHS was additionally adjusted for DNA source (blood vs. cheek) and cohort (NHSI vs. NHSII). As a sensitivity analysis, unadjusted models were run in all studies to assess whether the UKG results might be confounded by age; no differences in association were observed (data not shown). Secondary analyses examined the A1 and A2 alleles separately (information on A1 vs. A2 was not available in UKG), potential differences in association with histologic subtype (serous, mucinous, endometrioid) and potential effect modification by body mass index (BMI) and age. The BMI interaction was tested because the NHS previously reported a stronger ovarian cancer association between blood types B and AB among overweight women compared to women with BMI \ 25 kg/m 2 [7] . To test for interactions with BMI and age, we included multiplicative interaction terms between BMI (\25 vs. C25) or age (\55 vs. C55) and each blood group in each of the individual studies, except the UKG, which did not have information on age and BMI. Subsequently, we meta-analyzed the betas and standard errors for the multiplicative interaction terms and used the p value for each meta-analyzed interaction term as p-interaction for each blood group-BMI combination.
Results
The distribution of the ABO SNPs was similar across the 8 studies (Table 1 ). All 3 SNPs were in Hardy-Weinberg equilibrium; the frequencies of the O, A, AB, B blood groups in controls were similar to those reported previously [15, 16] . In the combined studies, the A blood group was associated with an increased risk of ovarian cancer (OR: 1.09; 95 % CI: 1.01-1.18; p = 0.03) compared to the O blood group (Table 2) . However, when examining associations with diplotype, this association was only observed for the A/O, and not the A/A, diplotype (Table 3) . No statistically significant associations were observed for the B (OR: 1.03; 95% CI: 0.88-1.20; p = 0.76) or AB (OR: 1.09; 95 % CI: 0.89-1.33; p = 0.40) blood groups. When the A blood groups were further separated into the A1 and A2 alleles, only the A1 blood group was associated with increased risk of ovarian cancer (A1: OR: 1.15; 95 % CI: 1.02-1.30; p = 0.03; A2: OR: 1.02; 95 % CI: 0.85-1.22; p = 0.83; Table 4 ). As in the diplotype analysis above, only the A1/O diplotype was associated with increased ovarian cancer risk (Table 5 ). There was no evidence for heterogeneity across studies; p values for heterogeneity ranged from 0.22 to 0.84.
The associations were similar across the histologic subtypes (Supplemental Table 2 ), with the possible exception of the AB blood type, which was associated with statistically nonsignificant increased risk of endometrioid ovarian cancer (OR: 1.39; 95 % CI: 0.84-2.30). When stratified by BMI (\25 vs. C25 kg/m 2 ), the increased risk associated with the A blood type was limited to those with BMI C 25 (OR: 1.29; 95 % CI: 1.09-1.53) (Supplemental Table 2 ). However, the interaction was not statistically significant (p = 0.08). We found no evidence for an interaction with age (data not shown).
Discussion
In eight studies participating in the Ovarian Cancer Association Consortium (OCAC), we observed an increased risk of ovarian cancer for the A blood type. In diplotype analysis, this association was only observed in the AO, but not AA diplotype, indicating that this finding may be due to chance. However, the confidence interval for the AA diplotype was wide and the confidence intervals for the AO and AA diplotypes substantially overlapped. Given that the frequency of the AA diplotype was only *17 % among those with blood group A, we may have had low power to detect associations with this diplotype.
Most previous studies have reported increased ovarian cancer risk associated with the A blood group compared to the O group (ORs ranged from 1.17 to 1.28) [3] [4] [5] [6] . These studies compared blood group distributions in ovarian cancer cases compared to large groups of controls. However, many of these studies have potential flaws, including the use of male controls, hospital controls, lack of adjustment for potential confounders, such as age and race, and control groups recruited at different times than the case groups, all of which could introduce bias into their results, as discussed in detail by Gates et al. [7] . Further, because previous studies relied on self-reported or serotyped blood group, they could not assess associations with specific diplotypes; ours is the first study to examine blood group diplotypes in relation to ovarian cancer risk. In a recent study of self-reported blood type and ovarian cancer risk from the NHS [7] , we observed an increased risk of ovarian cancer among women with any B allele (i.e., blood groups B and AB) compared to women with the O blood type (RR = 1.41; 95 % CI: 1.06-1.88). In the NHS nested case-control study, the concordance between self-reported blood type and genotype-derived blood group was 88 %, similar to what has previously been reported [16] . However, NHS women tended to overreport the less common blood groups (B and AB; Supplemental Table 3) ; an additional 40 % of NHS women did not know their blood type; these two sources of error combined may have led to a false-positive result for types B and AB in the previous analysis in NHS. The previous studies that found increased risk with blood group A had blood group data from serologic testing rather than self-report [3] [4] [5] [6] ; thus, the likelihood of misclassified blood groups was much lower in those studies.
The potential mechanisms linking blood group to ovarian cancer risk are unclear. As discussed in the recent manuscript by Gates et al. [7] , ABO blood type has been linked to immune surveillance and to blood levels of soluble ICAM-1, tumor necrosis factor alpha, and soluble E-selectin, which are associated with cell adhesion and apoptosis. However, these mechanistic links do not explain why the A blood type would confer ovarian cancer susceptibility. Notably, although ICAM-1 has been associated with ABO blood group in three studies, the A type was associated with lower ICAM-1 levels in two of the three studies [12, 17] , which is the opposite result than would be expected if the A blood group is promoting tumor aggressiveness. Further, in the two studies that observed associations between ABO and E-selectin, the A blood group was associated with lower levels of E-selectin compared to O in one [18] and levels did not differ between the blood groups O and A in the other [19] . Thus, it seems unlikely that the association between blood group A and ovarian cancer risk is being driven through altered cellular adhesion and motility. Alternately, it is possible that the ABO SNPs genotyped here are in linkage disequilibrium with variation in another genetic locus. Therefore, further research is needed to clarify the biologic mechanisms that link blood group to carcinogenesis.
There are two important limitations in the current study. First, controls in the UKG study were not selected at the same time as the cases and may not represent the population that gave rise to the cases. However, in a sensitivity analysis excluding the UKG study populations, the association with the A blood group was largely unchanged (Supplemental Table 4 ), suggesting that the UKG controls are not a large source of bias. Second, the current study had limited power for the analysis of subgroups, such as potential differences by histologic type, particularly for the less common types, such as clear cell. However, although not statistically significant within all groups, the results were largely consistent among the three most common histologic types (serous, endometrioid, and mucinous). Further, with 5,233 cases and 6,838 controls, this is the largest study of the association between ABO blood group and ovarian cancer to date, with 80 % power to detect a relative risk of 1.17 for the AB blood group, indicating that we had adequate power to detect modest associations with even the rarest blood group. Further, this study improves upon previous studies by using appropriate control groups as well as genotype-derived blood groups, which are less likely to suffer from misclassification compared to selfreported blood type. Additionally, the use of genotypederived blood groups allowed a more detailed investigation into diplotypes rather than the simple blood groups previously investigated.
In summary, our findings for blood group are consistent with previous findings of increased ovarian cancer risk with blood group A. Although potentially due to chance, the finding that this association is limited to the A1/O diplotype should be confirmed in additional studies. Given that the A blood type is associated with a modest increase in ovarian cancer risk, further research into the biologic mechanisms linking blood group with carcinogenesis is warranted.
